264 related articles for article (PubMed ID: 26523897)
21. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
22. Community-Acquired Pneumonia in Adults: Diagnosis and Management.
Kaysin A; Viera AJ
Am Fam Physician; 2016 Nov; 94(9):698-706. PubMed ID: 27929242
[TBL] [Abstract][Full Text] [Related]
23. The dilemma of monotherapy or combination therapy in community-acquired pneumonia.
Vardakas KZ; Trigkidis KK; Apiranthiti KN; Falagas ME
Eur J Clin Invest; 2017 Dec; 47(12):. PubMed ID: 29027205
[TBL] [Abstract][Full Text] [Related]
24. Beta-lactam versus beta- lactam/macrolide therapy in pediatric outpatient pneumonia.
Ambroggio L; Test M; Metlay JP; Graf TR; Blosky MA; Macaluso M; Shah SS
Pediatr Pulmonol; 2016 May; 51(5):541-8. PubMed ID: 26367389
[TBL] [Abstract][Full Text] [Related]
25. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
[TBL] [Abstract][Full Text] [Related]
26. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
[TBL] [Abstract][Full Text] [Related]
27. Atypical coverage in community-acquired pneumonia after outpatient beta-lactam monotherapy.
van Werkhoven CH; van de Garde EMW; Oosterheert JJ; Postma DF; Bonten MJM
Respir Med; 2017 Aug; 129():145-151. PubMed ID: 28732822
[TBL] [Abstract][Full Text] [Related]
28. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
[TBL] [Abstract][Full Text] [Related]
29. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
[TBL] [Abstract][Full Text] [Related]
30. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
31. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia].
Karaboğa B; Çilli A
Tuberk Toraks; 2015 Jun; 63(2):94-101. PubMed ID: 26167966
[TBL] [Abstract][Full Text] [Related]
33. Antibiotic treatment of moderate-severe community-acquired pneumonia: design and rationale of a multicentre cluster-randomised cross-over trial.
van Werkhoven CH; Postma DF; Oosterheert JJ; Bonten MJ
Neth J Med; 2014 Apr; 72(3):170-8. PubMed ID: 24846935
[TBL] [Abstract][Full Text] [Related]
34. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
Frei CR; Labreche MJ; Attridge RT
Drugs; 2011 Apr; 71(6):757-70. PubMed ID: 21504252
[TBL] [Abstract][Full Text] [Related]
35. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
36. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
Weiss K; Tillotson GS
Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
[TBL] [Abstract][Full Text] [Related]
37. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
[TBL] [Abstract][Full Text] [Related]
38. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
[TBL] [Abstract][Full Text] [Related]
39. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
40. In non-ICU suspected CAP, β-lactam was noninferior to β-lactam-macrolide or fluoroquinolone for 90-d mortality.
Fekete T
Ann Intern Med; 2015 Sep; 163(6):JC5. PubMed ID: 26370032
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
